Astrazeneca (AZN) Non-Current Receivables (2016 - 2026)

Astrazeneca has reported Non-Current Receivables over the past 18 years, most recently at $14.1 billion for Q1 2026.

For Q1 2026, Non-Current Receivables rose 6.46% year-over-year to $14.1 billion; the TTM value through Mar 2026 reached $14.1 billion, up 6.46%, while the annual FY2025 figure was $15.2 billion, 1531.94% up from the prior year.
Non-Current Receivables for Q1 2026 was $14.1 billion at Astrazeneca, down from $15.2 billion in the prior quarter.
Over five years, Non-Current Receivables peaked at $15.2 billion in Q4 2025 and troughed at $803.0 million in Q4 2023.
A 5-year average of $9.8 billion and a median of $11.1 billion in 2024 define the central range for Non-Current Receivables.
Biggest five-year swings in Non-Current Receivables: decreased 6.7% in 2022 and later surged 1531.94% in 2025.
Year by year, Non-Current Receivables stood at $835.0 million in 2022, then dropped by 3.83% to $803.0 million in 2023, then rose by 15.82% to $930.0 million in 2024, then surged by 1531.94% to $15.2 billion in 2025, then decreased by 7.06% to $14.1 billion in 2026.
Business Quant data shows Non-Current Receivables for AZN at $14.1 billion in Q1 2026, $15.2 billion in Q4 2025, and $14.3 billion in Q3 2025.

Peer Comparison